Skip to main content

Response to “Avoiding Methodological Bias in Studies of Amyloid Imaging Results Disclosure”

The Original Article was published on 04 June 2019

The goal of “Reactions to learning a ‘not elevated’ amyloid PET result in a preclinical Alzheimer’s disease trial” was to study how learning one is not eligible for a trial based on an Alzheimer’s disease (AD) biomarker result affects willingness to be in subsequent trials, as well as how it affects other behaviors [1]. Answering this question fills a critical gap in the literature, as preclinical AD trials are increasingly common but the ideal criteria for participant inclusion remains an area of active research. Thus, a person ineligible for one trial may be eligible for another.

Taswell and colleagues correctly observe that our study did not include a comparison group, which would have necessarily been individuals who demonstrated elevated amyloid and therefore were eligible for randomization in the preclinical AD trial [2]. The primary question under study—whether a subject who screen-fails for one AD trial is willing to participate in subsequent trials—was not applicable to this population. Their exclusion is not a bias. It was not necessary.

Looking more broadly, the gist of Taswell and colleagues’ commentary is a sensible summary of social science research. Multiple methods, and indeed multiple studies, are needed to arrive at a common understanding of the way the world is and how it can be changed. Only then can high confidence be achieved. In the nascent space of preclinical AD trials, much remains to be learned and a breadth of research designs and methods will be essential to advancing the field.


  1. Grill JD et al. Reactions to learning a “not elevated” amyloid PET result in a preclinical Alzheimer’s disease trial. Alzheimers Res Ther 2018;10:125

  2. Taswell et al. Avoiding methodological bias in studies of amyloid imaging results disclosure. Alzheimers Res Ther 2019.

Download references


There are no acknowledgements.


There was no funding for this letter.

Availability of data and materials

No data were involved in this letter.

Author information

Authors and Affiliations



Each author contributed to the writing of this letter. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Joshua D. Grill.

Ethics declarations

Ethics approval and consent to participate

Ethics approval was not necessary for this letter.

Consent for publication

We provide consent for publication.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grill, J.D., Cox, C.G., Harkins, K. et al. Response to “Avoiding Methodological Bias in Studies of Amyloid Imaging Results Disclosure”. Alz Res Therapy 11, 51 (2019).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: